Citations

Clear

3030 citation(s) found for "Susan, M".

Neurovascular Protective Function of Endothelial Nitric Oxide – Recent Advances –
Katušić, Zvonimir S. , Austin, Susan A.

Mayo Clinic

Circulation Journal | May 24, 2016 | Volume: 80 | Issue: 7 | Pages: 1499-1503

10.1253/circj.cj-16-0423 | PMID 27238834 Get It

Abstract B143: Pharmacogenomic of refractory response to R-CHOP therapy in diffuse large B-cell lymphoma (DLBCL) patients
Breitenstein, Matthew K. , Novak, Anne J. , Thompson, Carrie A. , Olswold, Curtis L., Nowakowski, Grzegorz S. , Ansell, Stephen M. , Weinshilboum, Richard M. , Wang, Liewei , Slager, Susan L. , Maurer, Matthew J. , Farooq, Umar , Link, Brian K. , Habermann, Thomas M. , Feldman, Andrew L. , Witzig, Thomas E. , Weinshilboum, Richard M. , Cerhan, James R.

Mayo Clinic

Molecular Cancer Therapeutics | May 20, 2016 | Volume: 14 | Issue: 12_Supplement_2 | Pages: B143-B143

10.1158/1535-7163.targ-15-b143 Get It

Abstract Background: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy is standard of care for patients with newly diagnosed DLBCL. A majority of patients respond to R-CHOP, however ∼9% will have primary refractory disease and outcomes in these patients are extremely poor. While there is some knowledge of the pharmacogenomic (PGx) determinants of individual agents within R-CHOP, little is known about the PGx determinants of combination therapy. Our study aims to elucidate germline PGx determinants of drug bioavailability and undesirable side chain reactions in DLBCL patients treated with R-CHOP having potential to influence refractory disease. Methods: Newly diagnosed, DLBCL patients treated with R-CHOP between 2002 and 2012 with germline DNA and genotyping data were selected from the Molecular Epidemiology Resource within the Iowa/Mayo Lymphoma SPORE. Refractory disease was defined as either i) a best response of stable or progressive disease or ii) progressive disease by the end of the planned number of cycles of R-CHOP. PGx candidates within known pharmacokinetics and pharmacodynamics (PD) pathways for 11 genes (1,040 single nucleotide polymorphisms (SNPs)) were selected for study (CPT 2012;92(4):414-7). Odds ratios (ORs) and 95% confidence intervals (CI) were used to estimate the association of SNPs with refractory disease, controlling for age, gender, and age-adjusted International Prognostic Index. Results: The median age at diagnosis of 424 of DLBCL patients treated with R-CHOP was 62 years (range 18-92); 45.7% were female; and 58.4% had Ann Arbor Stage III-IV. By the end of initial therapy 40 patients had primary refractory disease. Of the 1,040 SNPs evaluated, 120 (12%) were significantly associated with refractory disease at the 5% significance threshold suggesting novel associations with drug metabolism. The top SNP from each PGx candidate gene are shown in Table, with ALDH5A1 and CYP2B6 showing the most significant associations. Conclusions: While needing replication, we identified associations within two PGx candidate genes that are potentially functionally related to cyclophosphamide PD: alleles within CYP2B6 may have relevance in R-CHOP outcomes due to potential competition with other drug metabolizing enzymes shared with prednisone and vincristine biotransformation in the liver, and alleles withinALDH5A1 may impact a deactivating side chain reaction in B lymphocytes. Table: R-CHOP PGx candidates with known side chain reactionsPGx candidaten SNPsTop SNPChrOR* (95% CI)P-valueMAFABCB1365rs3480093571.86 (1.14 – 3.04)1.32E-020.29ADH1A32rs122996841.66 (0.60 - 4.53)3.27E-010.038ALDH3A116rs2228100171.26 (0.71 - 2.22)4.28E-010.24ALDH5A1192rs946103466.30 (2.43 - 16.4)1.55E-040.030CBR110rs2835266212.10 (0.90 - 4.89)8.76E-020.052CBR356rs45527331212.12 (0.91 - 4.98)8.29E-020.050CYP2B6107rs1038376192.38 (1.44 - 3.94)7.74E-040.27CYP3A421rs2898858372.32 (0.80 - 6.78)1.23E-010.028CYP3A531rs778032871.69 (0.68 - 4.16)2.57E-010.054SLC22A16193rs11217403561.80 (1.06 - 3.03)2.78E-020.21SOD116rs1041740211.35 (0.83 - 2.19)2.26E-010.32Chr=chromosome, MAF=minor allele frequency, *Adjusted for age, sex, and age-adjusted International Prognostic Index Citation Format: Matthew K. Breitenstein, Susan L. Slager, Anne J. Novak, Matthew J. Maurer, Carrie A. Thompson, Umar Farooq, Brian K. Link, Thomas M. Habermann, Curtis L. Olswold, Andrew L. Feldman, Grzegorz S. Nowakowski, Stephen M. Ansell, Thomas E. Witzig, Richard M. Weinshilboum, Liewei Wang, James R. Cerhan. Pharmacogenomic of refractory response to R-CHOP therapy in diffuse large B-cell lymphoma (DLBCL) patients. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B143.
Abstract C43: Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors
Beg, Muhammad Shaalan , Sachdev, Jasgit C. , Ejadi, Samuel, Kang, Y.-K., Lim, Ho Yeong , Kim, T-Y, Bader, Andreas G. , Stoudemire, Jay, Smith, Susan, Kim, Sinil, Brenner, Andrew Jacob , Borad, Mitesh J. , Kim, T-Y, Smith, Susan, Hong, David S.

Mayo Clinic

Molecular Cancer Therapeutics | May 20, 2016 | Volume: 14 | Issue: 12_Supplement_2 | Pages: C43-C43

10.1158/1535-7163.targ-15-c43 Get It

Abstract Background: MRX34 is a liposomal nanoparticle formulation with an encapsulated mimic of the naturally occurring microRNA-34 (miR-34), which is lost or expressed at reduced levels in many tumors. miR-34 inhibits key oncogenic pathways by repressing multiple important oncogenes including BCL2, E2F3, HDAC1, MET, MEK1, CDK4/6, PDGFR-ɑ/β, SIRT1, WNT1/3, NOTCH-1, β-catenin, CD44, Nanog and AXL. miR-34 also represses the expression of PD-L1 and DGKζ, thereby possibly triggering an anti-tumor immune response and cancer cell death. A multicenter Phase 1 clinical trial of MRX34 is being conducted in patients with advanced malignancies. Methods: Eligible patients were enrolled in a standard 3 + 3 dose escalation study and were given a MRX34 starting dose of 10 mg/m2, administered intravenously (IV) twice weekly (BIW) for 3 weeks in 28-day cycles. Enrollment is ongoing into a second MRX34 dosing schedule, daily x 5 (QD x 5) in 21-day cycles. The primary objectives are to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for the two dosing schedules. Secondary objectives include assessments of safety, tolerability and the pharmacokinetic profile of MRX34 after intravenous dosing as well as to assess any biological and clinical activity. Results: As of July 2015, 75 patients with advanced solid tumors were enrolled and evaluable: 44 Caucasians, 47 males, a median age of 61 years and a median of 4 prior treatments. Histologies included 30 hepatocellular carcinoma (HCC), 7 pancreatic cancer, 4 cholangiocarcinoma, 3 each of bladder, breast, colorectal, cervix and lung. The remaining 19 patients represented various other malignancies <3 patients each. The 110 mg/m2 was deemed to be the MTD for the BIW dosing schedule. The MTD has not been determined yet for the QD x 5 schedule and dose escalation is continuing. The current dose levels are 70 mg/m2 QD x 5 for HCC and 93 mg/m2 QD x 5 for other solid tumors. The following treatment-emergent, all-causality adverse events (AEs) were most frequent among 47 patients in BIW cohorts vs 28 patients in QD x 5 cohorts: fever (64% vs 61%), fatigue (57% vs 39%), chills (57% vs 36%), back pain (55% vs 36%), nausea (49% vs 39%), diarrhea (43% vs 11%), headache (34% vs 14%), vomiting (32% vs 11%), anorexia (26% vs 14%), abdominal pain (23% vs 21%), dyspnea (23% vs 14%), insomnia (23% vs 14%), and dehydration (23% vs 4%). Most frequent grade 3/4 laboratory abnormalities were: lymphopenia (36% vs 71%), neutropenia (26% vs 36%), hyponatremia (26% vs 7%), AST elevation (26% vs 29%), leukopenia (23% vs 36%), hyperglycemia (19% vs 36%), thrombocytopenia (17% vs 29%), anemia (11% vs 21%), alkaline phosphatase elevation (11% vs 21%), and ALT elevation (9% vs 21%). One patient with HCC and another patient with melanoma achieved confirmed partial responses per RECIST. Conclusions: MRX34 has a manageable safety profile with confirmed partial responses in two patients with advanced HCC and melanoma. Due to better tolerability, QD x 5 schedule has been chosen for further study. Following MTD determination, enrollment will soon begin into the QD x 5 expansion cohorts for selected tumors. Citation Format: Muhammad Shaalan Beg, Andrew Brenner, Jasgit Sachdev, Samuel Ejadi, Mitesh Borad, Yang-Kon Kang, Ho Lim, T-Y Kim, Andreas Bader, Jay Stoudemire, Susan Smith, Sinil Kim, David Hong. Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C43.
Abstract A50: Mitochondrial metabolism gene variants are associated with risk and survival in epithelial ovarian cancer (EOC)
Chornokur, Ganna , Schildkraut, Joellen M. , Goode, Ellen L. , Gayther, Simon A. , Sellers, Thomas A. , Phelan, Catherine M., Lin, Hui‐Yi , Monteiro, Álvaro N.A. , Pharoah, Paul D.P. , Ramus, Susan J.

Mayo Clinic

Molecular Cancer Research | May 20, 2016 | Volume: 14 | Issue: 1_Supplement | Pages: A50-A50

10.1158/1557-3125.metca15-a50 Get It

Abstract Background: Epithelial Ovarian Cancer (EOC) is a lethal gynecologic malignancy. Mitochondria are cellular organelles that regulate energy metabolism and are the primary source of reactive oxygen species (ROS), which damage both the nuclear and mitochondria DNA (mtDNA), contributing to the pathogenesis of EOC. Previously, we identified statistically significant EOC risk associations with 54 single nucleotide polymorphisms (SNPs) from 11 mitochondria-related genes in a study of 1815 EOC cases and 1900 controls. In this replication study we expand our investigation of mitochondrial metabolism genetic variants and associations with EOC risk and overall survival (OS). Methods: In a discovery set of 3761 EOC cases and 2722 controls, we investigated risk associations in 4200 SNPs from 130 mitochondrial metabolism genes. We genotyped 431 of the most significant SNPs from 86 genes in 14,525 EOC cases and 23,447 controls (of European ancestry) from 43 studies in OCAC using an Illumina Infinium iSelect BeadChip. Risk analyses were conducted using unconditional logistic regression under a log-additive model and adjusted for study site and the first five principal components of population substructure. Both invasive cancers combined and the four main histological subtypes were analyzed. Survival analyses were conducted on the same SNPs using Cox hazards models to estimate hazard ratios (HRs) and 95% CIs considering overall survival in 10,084 cases from 28 OCAC studies. We adjusted for multiple tests using False Discovery Rate q<20%. Results: The strongest evidence of an association for risk of invasive cancers combined and the serous subtype was SNP rs3096 in the pyridoxamine 5'-phosphate oxidase (PNPO) gene (OR=1.08, p=2.8x10-6). In clear cell carcinoma, the strongest association was a missense coding SNP rs28379632 (Ile421Met) in the MT-CYB gene (OR=4.0, p=0.003). For endometrioid cancer rs9330440 in the UNQ6494 gene was most significant (OR=0.89, p=0.001) while rs10267797 in the dihydrolipoamide dehydrogenase (DLD) gene was most significant in the mucinous subtype (OR=1.15, p=0.004). The strongest association with overall survival was mitochondrial transcription termination factor 1 (MTERF) rs2540571 (HR=0.92, p= 0.00011). Conclusion: These results suggest that mitochondrial metabolism gene variants appear to be associated with EOC risk and survival. Citation Format: Ganna Chornokur, Hui-Yi Lin, Alvaro Monteiro, Joellen Schildkraut, Ellen L. Goode, Paul DP Pharoah, Simon A. Gayther, Susan Ramus, Thomas A. Sellers, Catherine M. Phelan. Mitochondrial metabolism gene variants are associated with risk and survival in epithelial ovarian cancer (EOC). [abstract]. In: Proceedings of the AACR Special Conference: Metabolism and Cancer; Jun 7-10, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(1_Suppl):Abstract nr A50.
Abstract B27: Investigation of small GTPase genes in epithelial ovarian cancer.
Marchion, Douglas C. , Schildkraut, Joellen M. , Goode, Ellen L. , Gayther, Simon A. , Narod, Steven A. , Sellers, Thomas A. , Phelan, Catherine M., Lin, Hui‐Yi , Xiong, Yin , Tyrer, Jonathan P. , Monteiro, Álvaro N.A. , Berchuck, Andrew , Ramus, Susan J. , Pharoah, Paul D.P.

Mayo Clinic

Clinical Cancer Research | May 20, 2016 | Volume: 22 | Issue: 2_Supplement | Pages: B27-B27

10.1158/1557-3265.ovca15-b27 Get It

Abstract Background: Epithelial Ovarian Cancer (EOC) is a lethal gynecologic malignancy and the fifth cause of cancer mortality in women in the US. Normal ovarian physiology is intricately connected to tightly regulated small GTP binding proteins of the Ras superfamily (Ras, Rac, Rho, Rab, Arf, and Ran) which regulate key cellular processes such as signal transduction, cell proliferation, cell motility, and vesicle transport. These proteins function in a highly coordinated manner through signaling cascades and feedback loops within and among the small GTPase subfamilies. We hypothesized that single nucleotide polymorphisms (SNPs) in small GTPase genes are associated with epithelial ovarian cancer (EOC) risk and aberrant expression of these genes correlates with tumor characteristics including overall survival (OS). Methods: In a discovery set of 7931 EOC cases and 9206 controls we investigated 9,356 SNPs from 112 genes, 657 of which showed associations up to the significance level of p<0.05. We genotyped 407 of the most significant SNPs from 112 genes in a combined dataset (discovery and replication) which consisted of 18,736 EOC cases and 23,448 controls (of European ancestry) from 43 studies in the Ovarian Cancer Association Consortium (OCAC), using an Illumina Infinium iSelect BeadChip as part of the Collaborative Oncological Gene-environment Study (COGS). Odds ratios and 95% confidence intervals were calculated using unconditional logistic regression under log-additive models. A False Discovery Rate (FDR) q<0.2 was applied. Pearson's correlation tests were performed on the expression of genes with tumor characteristics and OS in 561 ovarian tumors: serous (n=464); endometrioid (n=52); clear cell carcinoma (n=28) and mucinous (n=17) subtypes. Results: The most significantly associated SNP associations with EOC were: AKAP6 rs1955513, (OR=0.9, p=3.3x10-4) in all invasive; ARGHEF10L rs10788679, (OR=1.05, p=2.6x10-4) in serous; RAB31 rs1166373, (OR=1.25, p=4.0x10-3) in endometrioid; KRAS rs4963872, (OR=1.35, P=4.5x10-4) in mucinous EOC and TNIK rs6780532, (OR=0.88, p=7.7x10-3) in clear cell carcinoma. Increased expression of AKAP6 and TNIK was marginally correlated with advanced EOC stage (p<0.05) while high KRAS expression was correlated with OS (HR=1.18, p=0.038). Conclusions: Genetic variation in the small GTPase genes appears to be associated with ovarian cancer risk and aberrant expression of these genes correlates with tumor characteristics and OS. Citation Format: Hui-Yi Lin, Yin Xiong, Jonathan Tyrer, Douglas C. Marchion, Alvaro NA Monteiro, Andrew Berchuck, Joellen M. Schildkraut, Ellen L. Goode, Susan J. Ramus, Simon A. Gayther, Paul DP Pharoah, Steven A. Narod, Thomas A. Sellers, Catherine M. Phelan. Investigation of small GTPase genes in epithelial ovarian cancer. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr B27.
Role Modeling and Regional Health Care Intensity: U.S. Medical Student Attitudes Toward and Experiences With Cost-Conscious Care
Starr, Stephanie R. , Mandrekar, Jay , Naessens, James M. , Tilburt, Jon C. , George, Paul , Baxley, Elizabeth G., Gonzalo, Jed D. , Moriates, Christopher , Goold, Susan Dorr , Miller, Bonnie M. , Grethlein, Sara J., Fancher, Tonya L. , Reed, Darcy A. , Leep Hunderfund, Andrea N, Hunderfund, Andrea N. Leep , Dyrbye, Liselotte N. , Carney, Patricia A. , Fancher, Tonya L

Mayo Clinic

Academic Medicine | May 18, 2016 | Volume: 92 | Issue: 5 | Pages: 694-702

10.1097/acm.0000000000001223 | PMID 27191841 Get It

Purpose To examine medical student attitudes toward cost-conscious care and whether regional health care intensity is associated with reported exposure to physician role-modeling behaviors related to cost-conscious care. Method Students at 10 U.S. medical schools were surveyed in 2015. Thirty-five items assessed attitudes toward, perceived barriers to and consequences of, and observed physician role-modeling behaviors related to cost-conscious care (using scales for cost-conscious and potentially wasteful behaviors; Cronbach alphas of 0.82 and 0.81, respectively). Regional health care intensity was measured using Dartmouth Atlas End-of-Life Chronic Illness Care data: ratio of physician visits per decedent compared with the U.S. average, ratio of specialty to primary care physician visits per decedent, and hospital care intensity index. Results Of 5,992 students invited, 3,395 (57%) responded. Ninety percent (2,640/2,932) agreed physicians have a responsibility to contain costs. However, 48% (1,1416/2,960) thought ordering a test is easier than explaining why it is unnecessary, and 58% (1,685/2,928) agreed ordering fewer tests will increase the risk of malpractice litigation. In adjusted linear regression analyses, students in higher-health-care-intensity regions reported observing significantly fewer cost-conscious role-modeling behaviors: For each one-unit increase in the three health care intensity measures, scores on the 21-point cost-conscious role-modeling scale decreased by 4.4 (SE 0.7), 3.2 (0.6), and 3.9 (0.6) points, respectively (all P < .001). Conclusions Medical students endorse barriers to cost-conscious care and encounter conflicting role-modeling behaviors, which are related to regional health care intensity. Enhancing role modeling in the learning environment may help prepare future physicians to address health care costs.
Application of Sociometers in the Emergency Department1
Blocker, Renaldo C., Yu, Denny , Hawthorne, Hunter J., Sır, Mustafa Y. , Hellmich, Thomas , Nestler, David M. , Hallbeck, M. Susan , Pasupathy, Kalyan S.

Mayo Clinic

Journal of Medical Devices | May 11, 2016 | Volume: 10 | Issue: 2 | Pages: No page available

10.1115/1.4033287 Get It

Age- and Sex-Specific Cancer Prevention and Screening Practices among Asian Indian Immigrants in the United States
Vadaparampil, Susan T. , Misra, Ranjita , Menon, Usha , BeLue, Rhonda

Mayo Clinic

Journal of Investigative Medicine | May 11, 2016 | Volume: 59 | Issue: 5 | Pages: 787-792

10.2310/jim.0b013e3182160d5d | PMID 21441831 Get It

Objective The objective was to examine age- and sex-specific cancer prevention and screening practices among 1820 Asian Indian (AI) adults in the United States using items from the 2000 National Health Interview Survey Cancer Control Topical Module. Methods A cross-sectional study of 1820 randomly selected AIs living in 7 US cities. Data were collected via telephone interviews by trained multilingual AI staff; the response rate was 62%. The primary outcome variables were age- and sex-specific cancer screening behaviors. Results Most of the AIs are men, married, educated, and with some form of health insurance. One fifth reported a family history of cancer. Adherence to mammography, Papanicolaou test, and clinical breast examination was higher in contrast to low rates of breast self-examination in women. Similarly, men reported low clinical testicular examination and fecal occult blood test, although prostate-specific antigen screening was higher than the reported rates among Asian Americans. Men were more likely to get a colonoscopy than women. The length of time in the United States had a relatively weak effect, and a family history of cancer had a moderate effect on screening behavior. Education and access to health care increased the odds (2-6 times) of cancer screening in AI men and women. Conclusions Cancer screening varies by educational level, years lived in the United States, and access to health care, among AIs living in the United States. Differences in sociodemographic factors should be considered to predict adherence to cancer screening guidelines and also be factored into patient education in this ethnic subgroup.
Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium
Cannioto, Rikki , LaMonte, Michael J. , Sucheston‐Campbell, Lara, Eng, Kevin H., Szender, J. Brian, Chang‐Claude, Jenny, Schmalfeldt, Barbara , Klapdor, R, Gower, Emily, Minlikeeva, Albina N. , Zirpoli, Gary , Edwards, Robert P., Goode, Ellen L. , Goodman, Marc T. , Høgdall, Estrid , Hosono, Satoyo , Jensen, Allan , Jordan, Susan J. , Group, on behalf of The Australian Ovarian Cancer Study, Matsuo, Keitaro , Ness, Roberta B., Olsen, Catherine M. , Olson, Sara H. , Pearce, Celeste Leigh , Pike, Malcolm C. , Rossing, Mary Anne, Szamreta, Elizabeth A. , Thompson, Pamela J., Tseng, Chiu-Chen , Vierkant, Robert A. , Webb, Penelope M. , Wentzensen, Nicolas , Wicklund, Kristine G. , Winham, Stacey J. , Wu, Anna H. , Schildkraut, Joellen M. , Terry, Kathryn L. , Kelemen, Linda E. , Moysich, Kirsten B. , Risch, Harvey A. , Hong, Chi‐Chen , Bandera, Elisa V. , Berchuck, Andrew , Cramer, Daniel W. , Doherty, Jennifer A. , Fridley, Brooke L. , Group, on behalf of The Australian Ovarian Cancer Study, Kjær, Susanne K. , Modugno, Francesmary , Winham, Stacey J , Webb, Penelope M , Jensen, Allan , Vierkant, Robert A , Moysich, Kirsten , Matsuo, Keitaro , Høgdall, Estrid , Zirpoli, Gary , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 7, 2016 | Volume: 25 | Issue: 7 | Pages: 1114-1124

10.1158/1055-9965.epi-15-1330 | PMID 27197285 Get It

Abstract Background: Despite a large body of literature evaluating the association between recreational physical activity and epithelial ovarian cancer (EOC) risk, the extant evidence is inconclusive, and little is known about the independent association between recreational physical inactivity and EOC risk. We conducted a pooled analysis of nine studies from the Ovarian Cancer Association Consortium to investigate the association between chronic recreational physical inactivity and EOC risk. Methods: In accordance with the 2008 Physical Activity Guidelines for Americans, women reporting no regular, weekly recreational physical activity were classified as inactive. Multivariable logistic regression was utilized to estimate the ORs and 95% confidence intervals (CI) for the association between inactivity and EOC risk overall and by subgroups based upon histotype, menopausal status, race, and body mass index. Results: The current analysis included data from 8,309 EOC patients and 12,612 controls. We observed a significant positive association between inactivity and EOC risk (OR = 1.34; 95% CI, 1.14–1.57), and similar associations were observed for each histotype. Conclusions: In this large pooled analysis examining the association between recreational physical inactivity and EOC risk, we observed consistent evidence of an association between chronic inactivity and all EOC histotypes. Impact: These data add to the growing body of evidence suggesting that inactivity is an independent risk factor for cancer. If the apparent association between inactivity and EOC risk is substantiated, additional work via targeted interventions should be pursued to characterize the dose of activity required to mitigate the risk of this highly fatal disease. Cancer Epidemiol Biomarkers Prev; 25(7); 1114–24. ©2016 AACR.
Simple Interventions Improve the Quality of a Missed Lab Appointment Process
Mookadam, Martina , Grover, Michael , Pullins, Chris, Winscott, Mary, Pierce, Susan, Pullins, Christopher , Pierce, Susan

Mayo Clinic

BMJ Quality Improvement Reports | May 5, 2016 | Volume: 5 | Issue: 1 | Pages: u205944.w2432

10.1136/bmjquality.u205944.w2432 | PMID 27239304 Get It

Simple interventions resolve the problem of missed lab appointments. It is essential that patients complete ordered laboratory studies. This maintains clinical quality and, potentially, keeps patients safe from harm. In our academic family medicine practice, baseline data demonstrated patients completed 94.7% of labs as ordered (26850/28348 patients per year) while 1498 (5.3%) did not. Our baseline patient reminder process, a mail or portal based generic letter, resulted in only 449 (30%) of patients ultimately completing them (1049 [70%] did not). Our baseline system was 96.3 % reliable. This process did not allow for provider review or input, and was not personalized for patients. We designed a quality improvement project involving three PDSA (Plan, Do, Study, and Act) cycles of about two months each. Desk staff created weekly reports of unresolved lab orders. A message in the electronic medical record (EMR) solicited provider input. Providers could elect to cancel studies (if already completed, reordered, or no longer clinically indicated) or have the patient receive a personalized reminder, including provider name and associated diagnoses. This reminder was sent by patient portal secure messaging (if an account existed) or with a mailed letter. These interventions resulted in 98.8 % process reliability. The frequency of unresolved lab orders decreased from 70% at baseline to 25%. In the second PDSA cycle, we contacted patients by the portal only if there was evidence of an active account. Otherwise, they were contacted by telephone. Patients without a portal account continued to receive a letter by mail. These modified processes resulted in an overall reliability rate of 99.2%. The frequency of unresolved lab orders decreased to 17%. A final PDSA cycle utilized only telephone contact with patients with unresolved lab orders. Schedulers offered patients a choice of appointment dates if they spoke personally. Otherwise, they were left messages with a future lab appointment date two weeks later.Overall process reliability now increased to 100%. The frequency of unresolved lab orders decreased to 0%. Our interventions resulted in increased system reliability.Provider input was not perceived as burdensome. Desk staff work effort was not increased.Telephone patient contact resulted in more frequent lab order completion than other methods.